

Z-D-Leu-CH=N<sub>2</sub>, 118248-00-3; Z-β-homo-D-Leu-OMe, 118248-01-4; BOC-D-Trp-OSu, 22220-11-7; Z-Asp(OBu-*t*)-OH, 5545-52-8; Z-Asp(OBu-*t*)-CH=N<sub>2</sub>, 118248-02-5; Z-β-homo-Asp(OBu-*t*)-OMe, 83436-44-6; BOC-Leu-OSu, 3392-09-4; H-Leu-β-homo-Asp-Phe-NH<sub>2</sub>·TFA, 118248-04-7; Z-D-Asp(OBu-*t*)-OH, 71449-08-6; Z-D-Asp(OBu-*t*)-CH=N<sub>2</sub>, 118248-05-8; Z-β-homo-D-Asp(OBu-*t*)-OMe, 118248-06-9; BOC-D-Leu-OSu, 60111-76-4; Z-Phe-OH, 1161-13-3;

Z-Phe-CH=N<sub>2</sub>, 15196-02-8; Z-β-homo-Phe-OMe, 97206-05-8; BOC-Asp(OBzl)-OH, 7536-58-5; BOC-Leu-OH, 13139-15-6; H-Phe-NH<sub>2</sub>, 5241-58-7; gastrin, 9002-76-0.

**Supplementary Material Available:** Tables of <sup>1</sup>H NMR data and assignments for compounds 1-17 (11 pages). Ordering information is given on any current masthead page.

### 3-Aminopyridazine Derivatives with Atypical Antidepressant, Serotonergic, and Dopaminergic Activities

Camille-Georges Wermuth,<sup>\*,†</sup> Gilbert Schlewer,<sup>†</sup> Jean-Jacques Bourguignon,<sup>†</sup> Georges Maghioros,<sup>†</sup> Marie-Jeanne Bouchet,<sup>†</sup> Claudine Moire,<sup>†</sup> Jean-Paul Kan,<sup>†</sup> Paul Worms,<sup>†</sup> and Kathleen Biziere<sup>†,§</sup>

Departement de Pharmacochimie Moléculaire, Centre de Neurochimie du CNRS, Université Louis Pasteur, 67084 Strasbourg Cedex, France, and Sanofi Recherche, 34082 Montpellier Cedex, France. Received May 23, 1988

Minaprine [3-[(β-morpholinoethyl)amino]-4-methyl-6-phenylpyridazine dihydrochloride] is active in most animal models of depression and exhibits in vivo a dual dopaminomimetic and serotoninomimetic activity profile. In an attempt to dissociate these two effects and to characterize the responsible structural requirements, a series of 47 diversely substituted analogues of minaprine were synthesized and tested for their potential antidepressant, serotonergic, and dopaminergic activities. The structure-activity relationships show that dopaminergic and serotonergic activities can be dissociated. Serotonergic activity appears to be correlated mainly with the substituent in the 4-position of the pyridazine ring whereas the dopaminergic activity appears to be dependent on the presence, or in the formation, of a para-hydroxylated aryl ring in the 6-position of the pyridazine ring.

Minaprine [3-[(β-morpholinoethyl)amino]-4-methyl-6-phenylpyridazine dihydrochloride, 1] is a psychotropic drug that we synthesized<sup>1</sup> in continuation of our research on pyridazine derivatives.<sup>2-10</sup> In rodents, minaprine is active in most animal models of depression, is devoid of anticholinergic activity, and does not modify locomotor activity.<sup>11-13</sup> In humans, minaprine is well tolerated and has been shown to be more effective than placebo and equally efficient to maprotiline and nomifensine in the treatment of depressive disorders.<sup>14-18</sup> Minaprine is presently being extensively investigated as an antidepressant in most European countries and in the United States.


Biochemical and pharmacological studies show that in vivo minaprine enhances both serotonergic and dopaminergic transmission, but does not affect noradrenergic transmission.<sup>11,19-22</sup> In vitro, however, minaprine does not affect the uptake, the release, or the metabolism of serotonin and dopamine and does not interact with serotonin or dopamine receptors.<sup>13,19-21</sup> Thus, the mechanism(s) through which minaprine exhibits this dual serotoninomimetic and dopaminomimetic effect remain(s) unclear. Another question also arises, which is to investigate whether or not it is possible to dissociate these two effects by modifying the chemical structure of minaprine, and which are the structural requirements for each one of these effects.

In an attempt to approach these problems, we synthesized series of analogues of minaprine that were tested for their potential antidepressant, serotonergic, and dopaminergic activities. The main modifications concerned the basic side chain, the substituents in the 4-position of the pyridazine ring, and the exploration of the role and substitutions of the phenyl ring in the 6-position.

#### Chemistry

The two dominant aspects that characterized the synthesis of 3-[(aminoalkyl)amino]pyridazines were the creation of the pyridazinone ring, properly substituted in

**Scheme I.** Synthesis of Minaprine, a Generalizable Example for the Synthesis of 4,6-Disubstituted Analogues




positions 4 and 6, and the subsequent branching of the basic side chain. The original synthesis of minaprine

- (1) Wermuth, C. G.; Exinger, A. *Agressologie* 1972, 13, 285.
- (2) Wermuth, C. G. *Agressologie* 1965, 6, 383.
- (3) Laborit, H.; Wermuth, C. G.; Leterrier, F.; Baron, C. *Agressologie* 1965, 6, 401.
- (4) Laborit, H.; Weber, B.; Baron, C.; Delbarre, B.; Pavlovichova, H. *Agressologie* 1965, 6, 463.
- (5) Laborit, H.; Wermuth, C. G.; Weber, B.; Delbarre, B.; Chekler, C.; Baron, C.; Rosengarten, H. *Agressologie* 1965, 6, 415.
- (6) Leclerc, G.; Wermuth, C. G.; Schreiber, J. *Bull. Soc. Chim. Fr.* 1967, II, 1302.
- (7) Leclerc, G.; Wermuth, C. G. *Bull. Soc. Chim. Fr.* 1967, II, 1307.
- (8) Wermuth, C. G. *Eur. J. Med. Chem. (Chim. Ther.)* 1967, 2, 130.
- (9) Wermuth, C. G.; Leclerc, G.; Melounou, P. *Eur. J. Med. Chem. (Chim. Ther.)* 1970, 5, 141.
- (10) Wermuth, C. G.; Leclerc, G. *Eur. J. Med. Chem. (Chim. Ther.)* 1970, 5, 243.

<sup>†</sup> Département de Pharmacochimie Moléculaire.


<sup>†</sup> Sanofi Recherche.

<sup>§</sup> Present address: F. Hoffmann-La Roche and Co. Ltd., CH 4002 Basel, Switzerland.

**Scheme II.** Synthesis of Minaprine Analogues Starting from Primary Diamines

(method A)<sup>1-3</sup> was applicable to a great number of 4,6-disubstituted analogues and is outlined in Scheme I.

The first step of this synthesis involves a ketolization reaction between acetophenone (2) and pyruvic acid (3) to yield  $\alpha$ -methyl- $\beta$ -benzoyllactic acid (4). As observed earlier, pyruvic acid can be replaced by its homologues,<sup>23</sup> and such ketolizations are applicable to aliphatic<sup>24</sup> or alicyclic<sup>25-27</sup> ketones. The cyclocondensation of the  $\gamma$ -keto acid with hydrazine led to the hydroxydihydropyridazinone 5 or its analogues when the reaction was performed under very mild conditions and when a strictly stoichiometric quantity of hydrazine was used.<sup>24-27</sup> The tertiary alcoholic group of 5 was then easily dehydrated in an acidic medium, yielding the pyridazinones of type 6. However, these compounds could be directly obtained by treatment of the ketolic acids 4 with 1.5 equiv of hydrazine, the excess of hydrazine ensuring the basic dehydration of the intermediate hydroxydihydropyridazinone 5.<sup>28</sup> The last steps of the synthesis are the conversion of the pyridazinones 6 into the imino chlorides 7 by treatment with phosphorus oxy-

**Scheme III.** Alternative Synthesis of Pyridazinones Starting with Itaconic Anhydride

chloride and the nucleophilic displacement of the chlorine atom by the appropriate primary amine. The reactivity of the imino chlorides 7 toward nucleophilic attack is diminished by the adverse polarization of the adjacent C<sub>6</sub>-N<sub>1</sub> imino function and drastic conditions are sometimes necessary.<sup>29</sup> We found that addition of a stoichiometric amount of ammonium chloride (or of the hydrochloride of the primary amine needed for the nucleophilic substitution) allowed easier operating conditions and gave rise to compound 8 and its analogues in high yields. This can be explained by a temporary complexation of the imino chloride that facilitates the nucleophilic attack.<sup>30</sup>

In the case of substitutions involving primary diamines (ethylene-, propylene-, or butylenediamine,  $\alpha$ -methyl-ethylenediamine), the expected aminopyridazines 9 and 10 were always accompanied by the symmetrically disubstituted diamines 11 (Scheme II). In addition, the substitution using  $\alpha$ -methyl-ethylenediamine gave rise to a 2:1 mixture of regioisomers 9 and 10, the dominant compound 10 being substituted at the less hindered amino function (Scheme II).

We developed an alternative route for the synthesis of various pyridazinones involving the cyclocondensation of already unsaturated  $\gamma$ -keto acids.<sup>31</sup> This reaction took place with a shift of the  $\alpha$ -methylene double bond into the pyridazinone ring 13 (Scheme III). The starting 2-alkylidene-4-oxo-4-arylbutanoic acids 12 were prepared either by a Friedel-Crafts acylation of benzene (or a substituted benzene) with itaconic anhydride<sup>32</sup> or by ring opening of  $\alpha$ -alkylidene- $\beta$ -butenolides.<sup>33</sup>

The syntheses illustrated in Scheme IV were utilized to introduce functional groups such as cyano, carbethoxy, or carboxamido in the 4-position of the pyridazinones. The key intermediate was the 4-carbethoxy-6-phenylpyridazinone 15, which was prepared by alkylation of diethyl malonate with phenacyl chloride, cyclization of the keto diester 14 with hydrazine, and creation of the 4,5 double bond through bromine-acetic acid oxidation. Compound 15 was converted to its imino chloride 16 with use of phosphorus oxychloride. Ammonolysis of 16 yielded the carboxamido intermediate 18. The 4-cyano derivative was prepared from 15 by successive ammonolysis and phosphorus oxychloride treatment, the latter ensuring both the dehydration of the carboxamide function and the conversion of the pyridazinone into its imino chloride 21. The 3-chloro compounds 16, 18, and 21 were reacted with morpholinoethylamine as described above to give the analogues 17, 19, and 22. Various 3-[(aminoalkyl)-amino]pyridazines were prepared by these methods and are listed in Table I.

### Pharmacological Results and Discussion

The 3-amino-6-phenylpyridazine derivatives described in this study were evaluated in mice for possible antidepressant, serotoninomimetic and dopaminomimetic ac-

- (11) Bizière, K.; Kan, J. P.; Souilhac, J.; Muiyard, J. P.; Roncucci, R. *Arzneim. Forsch. (Drug Res.)* **1982**, 32II, 8, 824.
- (12) Biziere, K.; Worms, P.; Kan, J. P.; Mandel, P.; Garattini, S.; Roncucci, *Drugs Exp. Clin. Res.* **1985**, XI (12), 831.
- (13) Worms, P.; Kan, J. P.; Perio, A.; Wermuth, C. G.; Bizière, K.; Roncucci, R. *J. Pharmacol.* **1986**, 17, 126.
- (14) Mikus, P.; Bizière, K.; Bentel, U. *Clin. Trial J.* **1985**, 22, 477.
- (15) Radmayr, E.; Bizière, K.; Bentel, U. *Clin. Trial J.* **1986**, 23, 100.
- (16) Bohacek, N.; Ravic, M.; Bizière, K. *J. Clin. Psychopharmacol.* **1986**, 6, 320.
- (17) Bohacek, N.; Bizière, K.; Ravic, M. *Drugs Exp. Clin. Res.* **1987**, 13, 435.
- (18) Passeri, M.; Cucinotta, D.; DeMello, M.; Bizière, K. In *J. Geriatric Psychiat.* **1987**, 2, 97.
- (19) Kan, J. P.; Baudry, N.; Bougault, I.; Gonalons, N.; Garattini, S.; Bizière, K. *Acta Pharm. Biol. Clin.* **1983**, 2, 137.
- (20) Ferreti, P.; Algeri, S.; Benefati, F.; Cimino, M.; Ferreti, L.; Garattini, S.; Lipartiti, M. *J. Pharm. Pharmacol.* **1984**, 36, 48.
- (21) Garattini, S.; Forloni, G. L.; Tirelli, A. S.; Ladinsky, H.; Conso, S. *Psychopharmacology* **1984**, 82, 210.
- (22) Worms, P.; Gueudet, C.; Bizière, K. *Life Sci.* **1986**, 39, 2199.
- (23) Prasad, M.; Wermuth, C. G.; Schreiber, J. *Bull. Soc. Chim. Fr.* **1967**, II, 1379.
- (24) Armengaud, C.; Wermuth, C. G.; Schreiber, J. *C. R. Acad. Sci. (Paris)* **1962**, 254, 2181.
- (25) Prasad, M.; Wermuth, C. G.; Schreiber, J. *Bull. Soc. Chim. Fr.* **1967**, II, 1386.
- (26) Prasad, M.; Wermuth, C. G. *Bull. Soc. Chim. Fr.* **1968**, II, 264.
- (27) Prasad, M.; Wermuth, C. G. *Bull. Soc. Chim. Fr.* **1985**, II, 865.
- (28) Maghioros, G.; Schlewer, G.; Wermuth, C. G. *Bull. Soc. Chim. Fr.* **1985**, II, 865.

- (29) Restle, S.; Wermuth, C. G. *Tetrahedron Lett.* **1979**, 50, 483.
- (30) Maghioros, G.; Schlewer, G.; Wermuth, C. G.; Lagrange, J.; Lagrange, P. *Nouv. J. Chim.* **1983**, 7, 667.
- (31) Meyer, A., Thèse de Doctorat en Pharmacie, Strasbourg, 1978.
- (32) Exinger, A.; Wermuth, C. G. *Synthesis* **1974**, 817.
- (33) Filler, R.; Hebron, L. H. *J. Am. Chem. Soc.* **1958**, 81, 391.

Table I. Synthetic Methods and Physical Data for Minaprine Analogues and Key Intermediates

































no.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	mp, °C	formula	anal. ( <sup>1</sup> H NMR)					
							no.	method	mp, °C	no.	mp, °C
23	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>3</sub> -N 	196	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O·2HCl	CHN	6	A	(1) <sup>c</sup>	7	(1)
24	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	CH <sub>2</sub> CH(CH <sub>3</sub> )-N 	196	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O·HCl	CHN	6	A	(1)	7	(1)
25	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	173	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O·2HCl	CHN	6	A	(1)	7	(1)
26	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> NH <sub>2</sub>	230	C <sub>13</sub> H <sub>16</sub> N <sub>4</sub> ·2HCl·1/2H <sub>2</sub> O	CHN	6	A	(1)	7	(1)
27	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>3</sub> NH <sub>2</sub>	160	C <sub>14</sub> H <sub>18</sub> N <sub>4</sub> ·2HCl·H <sub>2</sub> O	CHN	6	A	(1)	7	(1)
28 <sup>c</sup>	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	CH(CH <sub>3</sub> )CH <sub>2</sub> NH <sub>2</sub>	271	C <sub>14</sub> H <sub>18</sub> N <sub>4</sub> ·2HCl·1/2H <sub>2</sub> O	CHN	6	A	(1)	7	(1)
	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	CH <sub>2</sub> CH(CH <sub>3</sub> )NH <sub>2</sub>				6	A	(1)	7	(1)
29	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>4</sub> NH <sub>2</sub>	170 dec	C <sub>15</sub> H <sub>20</sub> N <sub>4</sub> ·2HCl·H <sub>2</sub> O	CHN	6	A	(1)	7	(1)
30	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> NHCH <sub>3</sub>	252	C <sub>14</sub> H <sub>18</sub> N <sub>4</sub> ·2HCl·1/2H <sub>2</sub> O	CHN	6	A	(1)	7	(1)
31	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> N(CH <sub>3</sub> ) <sub>2</sub>	238 dec	C <sub>15</sub> H <sub>20</sub> N <sub>4</sub> ·2HCl	CHN	6	A	(1)	7	(1)
32	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub>	120	C <sub>17</sub> H <sub>24</sub> N <sub>4</sub> ·2 oxalate	CHN	6	A	(1)	7	(1)
33	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> N(mC <sub>3</sub> H <sub>7</sub> ) <sub>2</sub>	168	C <sub>19</sub> H <sub>28</sub> N <sub>4</sub> ·2 oxalate	CHN	6	A	(1)	7	(1)
34	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	148	C <sub>17</sub> H <sub>22</sub> N <sub>4</sub> ·2HCl	CHN	6	A	(1)	7	(1)
35	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	246	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> ·2HCl	CHN	6	A	(1)	7	(1)
36	H	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	231	C <sub>16</sub> H <sub>20</sub> N <sub>4</sub> O·2HCl	CHN		A	(37)		(42)
37	C <sub>2</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	172	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O·2HCl·2H <sub>2</sub> O	CHN		A	(40)		(40)
22	CN	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	144	C <sub>17</sub> H <sub>19</sub> N <sub>5</sub> O·2HCl·2H <sub>2</sub> O	CHN				21	206
19	CONH <sub>2</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	220	C <sub>17</sub> H <sub>21</sub> N <sub>5</sub> O·2HCl	CHN	20	b	300	18	204
17	CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	148	C <sub>19</sub> H <sub>24</sub> N <sub>4</sub> O <sub>3</sub> ·2HCl	CHN	15	b	150	16	60
38	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	214	C <sub>22</sub> H <sub>24</sub> N <sub>4</sub> O·2HCl	CHN					
39	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	207	C <sub>23</sub> H <sub>28</sub> N <sub>4</sub> O·2HCl	CHN	66	B	190	93	116
40	CH <sub>2</sub> -4'-Cl-C <sub>6</sub> H <sub>4</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	162	C <sub>23</sub> H <sub>25</sub> N <sub>4</sub> OCl·2HCl	CHN	67	B	179	94	151
41	CH <sub>2</sub> -2'-Cl-C <sub>6</sub> H <sub>4</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	213	C <sub>23</sub> H <sub>25</sub> N <sub>4</sub> OCl·2HCl	CHN	68	B	150	95	135
42	CH <sub>2</sub> -β-naphthyl	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	220 dec	C <sub>27</sub> H <sub>28</sub> N <sub>4</sub> O·2HCl·2H <sub>2</sub> O	CHN	69	B	194	96	124
43	CH <sub>3</sub>	4'-Cl-C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 		C <sub>17</sub> H <sub>21</sub> N <sub>4</sub> OCl·2HCl	CHN	70	A		97	
44	CH <sub>3</sub>	3'-Cl-C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	214	C <sub>17</sub> H <sub>21</sub> N <sub>4</sub> OCl·2HCl	CHN	71	A	(40)	98	112
45	CH <sub>3</sub>	2'-Cl-C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	219	C <sub>17</sub> H <sub>21</sub> N <sub>4</sub> OCl·2HCl	CHN	72	A	232	99	112
46	CH <sub>3</sub>	4'-F-C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	231	C <sub>17</sub> H <sub>21</sub> N <sub>4</sub> OF·2HCl	CHN	73	A	234	100	178
47	CH <sub>3</sub>	2'-F-C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	230	C <sub>17</sub> H <sub>21</sub> N <sub>4</sub> OF·2HCl	CHN	74	A	196	101	105
48	CH <sub>3</sub>	4'-CH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 		C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O·2HCl	CHN	75	A	(40)	102	(42)
49	CH <sub>3</sub>	3'-CH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	177	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O·2HCl	CHN	76	A	235	103	116
50	CH <sub>3</sub>	2'-CH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	189	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O·2HCl	CHN	77	A	185	104	175
51	CH <sub>3</sub>	4'-OCH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	162	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O <sub>2</sub> ·2HBr	CHN	78	A	228	105	115
52	CH <sub>3</sub>	3'-OCH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	220	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O <sub>2</sub> ·2HCl	CHN	79	A	188	106	88
53	CH <sub>3</sub>	2'-OCH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N 	224	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O <sub>2</sub> ·2HCl	CHN	80	A	210	107	96

Table I (Continued)

no.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	mp, °C	formula	anal. ( <sup>1</sup> H NMR)						
							no.	method	mp, °C	no.	mp, °C	
54	CH <sub>3</sub>	4'-NH <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O		C <sub>17</sub> H <sub>23</sub> N <sub>5</sub> O·2HCl·H <sub>2</sub> O	CHN	81	b		108	b	
55	CH <sub>3</sub>	4'-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O		C <sub>17</sub> H <sub>21</sub> N <sub>5</sub> O <sub>3</sub> ·2HCl·H <sub>2</sub> O	CHN	82	A	(42)	109	(42)	
56	CH <sub>3</sub>	4'-OH-C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O	170	C <sub>17</sub> H <sub>22</sub> N <sub>4</sub> O <sub>2</sub> ·2HBr	CHN	83	b	(40)	110	b	
57	CH <sub>3</sub>	3'-OH-C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O		C <sub>17</sub> H <sub>22</sub> N <sub>4</sub> O <sub>2</sub> ·2HBr	CHN	84	b		111	b	
58	CH <sub>3</sub>	2'-OH-C <sub>6</sub> H <sub>4</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O	162	C <sub>17</sub> H <sub>22</sub> N <sub>4</sub> O <sub>2</sub> ·2HBr	CHN	85	b		112	b	
59	CH <sub>3</sub>	CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O	278	C <sub>12</sub> H <sub>20</sub> N <sub>4</sub> O·2HCl	CHN	86	A	129	113		
60	CH <sub>3</sub>	c-C <sub>6</sub> H <sub>11</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O	237	C <sub>17</sub> H <sub>28</sub> N <sub>4</sub> O·2HCl	CHN	87	A	173	114		
61	CH <sub>3</sub>	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O	160	C <sub>18</sub> H <sub>24</sub> N <sub>4</sub> O·2HCl	CHN	88	A	160	115	300	
62	CH <sub>3</sub>	α-naphthyl	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O	200	C <sub>21</sub> H <sub>24</sub> N <sub>4</sub> O·2HCl	CHN	89	A	(41)	116	(42)	
63	CH <sub>3</sub>	β-naphthyl	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O	200	C <sub>21</sub> H <sub>24</sub> N <sub>4</sub> O·2HCl	CHN	90	A		117		
64	CH <sub>3</sub>	2'-thienyl	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O	234	C <sub>15</sub> H <sub>20</sub> N <sub>4</sub> OS·2HCl	CHN	91	A	236	118	146	
65	CH <sub>3</sub>	3'-thienyl	(CH <sub>2</sub> ) <sub>2</sub> -N(CH <sub>2</sub> ) <sub>2</sub> O	152	C <sub>15</sub> H <sub>20</sub> N <sub>4</sub> OS·2HCl	CHN	92	A	246	119	171	

<sup>a</sup>3:1 mixture. <sup>b</sup>See special procedures. <sup>c</sup>Numbers in parentheses refer to reference numbers.

## Scheme IV. Synthesis of 4-Cyano, 4-Aminocarbonyl, and 4-Carboxy Analogues of Minaprine



activities. The antagonism of reserpine-induced ptosis was used to screen for antidepressant activity.<sup>34</sup> The potentiation of 5-hydroxytryptophan (5-HTP) was taken as an index of serotonergic activity.<sup>35</sup> The decrease of the

turning behavior induced by a unilateral striatal 6-hydroxydopamine lesion was considered as predictive of dopaminergic activity.<sup>36</sup> Minaprine and its analogues were

(34) Gouret, C.; Mocquet, G.; Coston, A.; Raynaud, G. *J. Pharmacol.* 1977, 8, 333.

(35) Lessin, A. W. *Biochem. Pharmacol.* 1973, 2, 290.

(36) Von Voigtlander, P. F.; Moore, K. E. *Neuropharmacology* 1973, 12, 451.

**Table II.** Pharmacological Data for Reference Compounds

	reserpine ptosis: ED <sub>50</sub> , mg/kg ip	potentiation 5-HTP: ED <sub>50</sub> , mg/kg ip	turning: MED, mg/kg ip
imipramine	2.3 (2.2–2.4)	In. <sup>b</sup> (>30)	In. (>20)
chlorimipramine	3.3 (1.8–4.1)	4.8 (3.0–7.9)	NT
nomifensine	0.17 (0.13–0.22)	In. (>30)	5 <sup>c</sup>
apomorphine	NT <sup>a</sup>	NT	0.05
(+)-amphetamine	NT	NT	2.5


<sup>a</sup> Not tested.

compared to five reference compounds: imipramine, chlorimipramine, nomifensine, apomorphine, and (+)-amphetamine. As shown in Table II, reserpine-induced ptosis was antagonized by the antidepressant drugs (ADDs) imipramine, chlorimipramine, and nomifensine; chlorimipramine was the only ADD to potentiate 5-HTP-induced tremor. The dopamine receptor agonist apomorphine decreased the spontaneous ipsilateral turning occurring in the lesioned mice, whereas nomifensine, a dopamine uptake inhibitor, and (+)-amphetamine, a dopamine releaser, both increased this behavior; imipramine was inactive in this latter model. Like the parent compound minaprine, most of the compounds tested induced seizures and were screened for antidepressant, serotoninomimetic, and dopaminomimetic activity at a dose not higher than 50% of the threshold dose inducing seizures. If a compound was found active at this dose, dose-response curves were generated, from which half-maximal effective values (ED<sub>50</sub>) were calculated by log-probit analysis. For turning experiments, a minimal effective dose (MED; *p* < 0.05) was generated.

The structure-activity relationships in this series were examined by various types of structural changes. The nature of the side chain on the exocyclic amine was modified. The effects of substituents in the 4-position of the

pyridazine ring were examined. The phenyl substituents were varied to test steric and electronic effects. Finally, the phenyl ring itself was replaced by other aromatic heteroaromatic and nonaromatic cycles.


As shown in Table III, lengthening the morpholinoethyl side chain to a 3-morpholinopropyl side chain led to compound **23**, which was inactive in all screening procedures but which still induced seizures with a potency comparable to that of the parent compound **1**. Replacing the morpholinoethyl side chain by a 2-morpholinopropyl side chain (**24**) or substituting the morpholine ring in the  $\alpha$  position by a methyl (**25**) yielded compounds that were weak antagonists of reserpine-induced ptosis (antidepressant activity). They were inactive in the 5-HTP potentiation test and in the turning model (5-HT and DA activities). Again, for compounds **24** and **25**, convulsant potency was not significantly different from that of the parent compound **1**. Replacing the morpholinoethyl side chain with an aminoethyl (**26**), a 3-aminopropyl (**27**), a 2-aminopropyl (**28**), or a 4-aminobutyl (**29**) side chain led to compounds that were poor antagonists of reserpine-induced ptosis and that did not potentiate 5-HTP. Compounds **26**, **27**, and **29** exhibited fairly potent dopaminomimetic activity as predicted by the turning behavior model; compound **28** was poorly active. Interestingly these compounds with a primary amine side chain were considerably less convulsant than the parent compound **1**. The monomethyl (**30**) and the dimethyl (**31**) derivatives were weak antagonists of reserpine-induced ptosis, were inactive in potentiating 5-HTP, and did not modify turning behavior. These compounds were weaker convulsants than compound **1**. The diethylamino (**32**), dipropylamino (**33**), pyrrolidino (**34**), and piperidino (**35**) derivatives were inactive in all screening procedures and were as potent as compound **1** in eliciting seizures. The results obtained by altering the morpholinoethyl side chain of the parent compound **1**

**Table III.** Pharmacological Results: The Effects of the Nature of the Amino Side Chain

no.	R <sub>3</sub>	acute toxicity: LD <sub>50</sub> , mg/kg ip	reserpine ptosis: ED <sub>50</sub> , mg/kg ip	potentiation 5-HTP: ED <sub>50</sub> , mg/kg ip	turning: MED, mg/kg ip
1		63	5 (4–7)	24 (19–31)	0.06
23		66	>30	>25	2
24		54	13 (11–16)	>15	2
25		110	20 (11–34)	30 <sup>b</sup>	>2
26	(CH <sub>2</sub> ) <sub>2</sub> NH <sub>2</sub>	300	16 (14–18)	>30	0.5
27	(CH <sub>2</sub> ) <sub>3</sub> NH <sub>2</sub>	300	50 <sup>b</sup>	>30	0.1
28	CH(CH <sub>3</sub> )CH <sub>2</sub> NH <sub>2</sub>	>200	34 (31–38)	>30	2
29	CH <sub>2</sub> CH(CH <sub>3</sub> )NH <sub>2</sub>	300	>50	>30	0.1
30	(CH <sub>2</sub> ) <sub>2</sub> NHCH <sub>3</sub>	>200	36 (24–55)	≥30	2
31	(CH <sub>2</sub> ) <sub>2</sub> N(CH <sub>3</sub> ) <sub>2</sub>	118	29 (27–31)	>30	10
32	(CH <sub>2</sub> ) <sub>2</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub>	80	>30	>30	>10
33	(CH <sub>2</sub> ) <sub>2</sub> N(nC <sub>3</sub> H <sub>7</sub> ) <sub>2</sub>	76	>30	>30	2
34		70	>30	NT <sup>a</sup>	NT <sup>a</sup>
35		37	≥10	>10	2

<sup>a</sup> NT: not tested. <sup>b</sup> 50% activity at this maximal tested dose.

Table IV. Pharmacological Results for 4-Substituted Analogues of Minaprine



no.	R <sub>1</sub>	acute toxicity: LD <sub>50</sub> , mg/kg ip	reserpine ptosis: ED <sub>50</sub> , mg/kg ip	potentiation 5-HTP: ED <sub>50</sub> , mg/kg ip	turning: MED, mg/kg ip
1	CH <sub>3</sub>	63	5.0 (4-7)	24 (19-31)	0.06
36	H	250	6.0 (5.9-6.7)	3.7 (3.0-4.0)	0.5
37	C <sub>2</sub> H <sub>5</sub>	31	>10	>10	2
22	CN	>250	6.6 (5.9-7.3)	5.0 (4.4-5.7)	0.1
19	CONH <sub>2</sub>	NT <sup>a</sup>	>40	>60	2
17	CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub>	180	>50	NT	0.5
38	C <sub>6</sub> H <sub>5</sub>	150	>50	>25	>2
39	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	131	>50	>50	2
40	CH <sub>2</sub> -4'-Cl-C <sub>6</sub> H <sub>4</sub>	180	>30	>30	10
41	CH <sub>2</sub> -2'-Cl-C <sub>6</sub> H <sub>4</sub>	95	>50	>50	10
42	CH <sub>2</sub> -β-naphthyl	275	>50	>100	2

<sup>a</sup>NT: not tested.

indicate that antidepressant, serotoninomimetic, and dopaminomimetic activities are not necessarily correlated to convulsant activity. Moreover, the primary amine derivatives 26-29 were fairly potent in the turning model and did not potentiate 5-HTP-induced tremor, suggesting that dopaminomimetic activity can be dissociated from serotoninomimetic activity. As far as overall activity is concerned, the parent compound 1 was clearly the most potent compound, emphasizing the importance of the morpholino group for activity.


The effects of substituents in the 4-position of the pyridazine ring are shown in Table IV. Suppressing (36) or replacing the methyl in the 4-position by a cyano group (22) led to compounds that were as active as 1 in antagonizing reserpine-induced ptosis, more active in potentiating 5-HTP-induced tremors, and slightly less active in the turning model; moreover, these compounds were weaker convulsants than 1. All the other substitutions in the 4-position yielded compounds that were inactive, with the exception of compound 17, which exhibited moderate dopaminomimetic activity. Thus the nature of the substituent in the 4-position is crucial for activity. Electronic factors are not involved since the 4-methyl-substituted compound 1 and the 4-cyano-substituted compound 22 exhibit comparable activities. Steric factors may be involved since more bulky substituents such as an ethyl in 37 or a phenyl in 38 in the 4-position led to inactive compounds. Another interpretation of these results could be that a readily metabolizable group in the 4-position is necessary for antidepressant, serotoninomimetic, and dopaminomimetic activities; one could hypothesize that the activities of compounds 1 and 22 could be due to their metabolism to the nonsubstituted derivative 36. In view of this hypothesis the virtual inactivity of compounds 17 and 19 is surprising since one would expect these compounds to be hydrolyzed to the corresponding 4-carboxylic derivative, which would yield compound 36 by decarboxylation. However, one cannot preclude simultaneous inactivating metabolic attacks of compounds 17 and 19 on the phenyl ring or on the (morpholinoethyl)amino side chain.

If we consider the convulsant activity, it can be seen that the nature of the substituent in the 4-position of the pyridazine ring also markedly affected this potency. Electronic, and not steric, factors seem to be involved for this activity. Substitution in the 4-position with electron-donating groups (1, 37) increased convulsant activity, whereas

substitution by electron-attracting groups 22 led to compounds that were weak convulsants. Steric factors in this position do not seem to affect convulsant activity, since the 4-methyl derivative 1 was considerably more potent than the 4-cyano derivative 22 in inducing seizures and derivatives with bulky substituents in the 4-position (38-42) were as weak as the unsubstituted compound 36 in inducing seizures.

The effects of various substituents on the phenyl ring in the 6-position in modifying the activity of the parent compound 1 is shown in Table V. Practically all the substitutions led to loss of activity with the exception of the 2'-hydroxy (58), 3'-methoxy (52), 4'-chloro (43), and 4'-fluoro (46) derivatives, which were mainly active in the reserpine and in the turning models, and the 4'-hydroxy (56) derivative, which exhibited selective dopaminomimetic activity. Interestingly the 4'-chloro and 4'-fluoro derivatives were poorly active in the turning model, although they were active in the other screening procedures, suggesting that para-hydroxylation is necessary for dopaminomimetic activity. The apparent loss of activity entailed by most of the substitutions on the phenyl ring should be interpreted with caution since, with the exception of the hydroxylated derivatives 56-58, the convulsant potency of these compounds was at best equal to that of the parent compound 1 and usually much greater. For this reason most of the compounds could not be tested at doses higher than 1-10 mg/kg, doses at which they were found inactive. With respect to the convulsant potency of these compounds, the 2'-substituted compounds were more potent than the corresponding 3'-substituted derivatives, which in turn were more convulsant than the 4'-substituted derivatives. Steric factors are probably involved since the 4'-chloro and the 4'-methyl derivatives are equipotent in inducing seizures. The relatively low convulsant potency of the hydroxylated derivatives is difficult to interpret since several factors may be involved such as metabolic degradation or low penetration into the brain.

Replacing the phenyl ring by a methyl group yielded a totally inactive compound 59, and replacing the phenyl ring by a cycloalkyl or other aromatic rings led to a dissociation between serotoninergic and dopaminergic activities. Thus the cyclohexyl (60) and the α- and β-thienyl derivatives (64, 65) were active as antidepressants and serotoninomimetics, whereas the α-naphthyl derivative (62) was selectively dopaminergic. The inactivity of the cyclohexyl and the α- and β-thienyl derivatives in the turning

**Table V.** Pharmacological Results: The Effects of the Aromatic Substitution in the Position 6

no.	R <sub>2</sub>	acute toxicity: LD <sub>50</sub> , mg/kg ip	reserpine ptosis: ED <sub>50</sub> , mg/kg ip	potentiation 5-HTP: ED <sub>50</sub> , mg/kg ip	turning: MED, mg/kg ip
1	C <sub>6</sub> H <sub>5</sub>	63	5 (4-7)	24 (19-31)	0.06
43	4'-Cl-C <sub>6</sub> H <sub>4</sub>	62	>10	5.8 (4.9-6.7)	>2
44	3'-Cl-C <sub>6</sub> H <sub>4</sub>	21	>10	>10	>2
45	2'-Cl-C <sub>6</sub> H <sub>4</sub>	7	>5	NT <sup>c</sup>	1
46	4'-F-C <sub>6</sub> H <sub>4</sub>	45	4.5 (1.9-10.7)	4.7 (1.9-11.7)	2
47	2'-F-C <sub>6</sub> H <sub>4</sub>	26	>10	>10	0.5
48	4'-CH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	51	>15	>15	0.5
49	3'-CH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	23	10 <sup>a</sup>	>10	>2
50	2'-CH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	5	>1	>1	>1
51	4'-OCH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	19	>5	>5	>2
52	3'-OCH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	18	6 (5-9)	>5	0.5
53	2'-OCH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	40	>10	>10	0.5
54	4'-NH <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	15	>5	NT	>2
55	4'-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	35	>10 (3.2-6.3)	>10	NT
56	4'-OH-C <sub>6</sub> H <sub>4</sub> <sup>b</sup>	>300	>40	>100	0.1
57	3'-OH-C <sub>6</sub> H <sub>4</sub>	>200	>50	>30	10
58	2'-OH-C <sub>6</sub> H <sub>4</sub>	>200	16 (16-20)	17 (17-20)	0.1
59	CH <sub>3</sub>	>100	>50	>50	>10
60	c-C <sub>6</sub> H <sub>11</sub>	43	4.5 (3.2-6.3)	16 (3.0-38)	>10
61	CH <sub>2</sub> -C <sub>6</sub> H <sub>5</sub>	30	>10	>10	2
62	α-naphthyl	7	>2.5	>2.5	0.01
63	β-naphthyl	23	>10	NT	>2
64	2'-thienyl	59	4.8 (4.0-5.7)	4.2 (3.8-4.9)	>10
65	3'-thienyl	72	10 (9.0-12.0)	1.7 (1.4-2.1)	>10

<sup>a</sup> 50% activity at this maximal tested dose. <sup>b</sup> See ref 46. <sup>c</sup> NT: not tested.

model could again be interpreted as indicating that para-hydroxylation is necessary for dopaminergic activity. The benzyl derivative 61 as well as the α- and β-naphthyl derivatives were more potent in inducing seizures than the parent compound 1, suggesting again that increasing the bulk of the substituent in the 6-position increases convulsant potency.

The structure-activity relationships in this series show that serotonergic, dopaminergic, and convulsant activities can be dissociated. Notably, the fact that serotonergic and dopaminergic activities are not always correlated strongly suggests that the serotoninomimetic and dopaminomimetic activities of the parent compound minaprine are mediated by different mechanisms and/or different active metabolites. Thus structure-activity relationships in this series should be analyzed in terms of potential metabolism as well as in terms of absolute structures. Serotonergic activity appears to be correlated mainly with the nature of the substituent in the 4-position of the pyridazine ring, but is also influenced by the nature of the side chain in the 3-position of this ring. The dopaminergic activity appears to be mainly dependent on the possibility of a para-hydroxylation of the heteroaromatic substituent in the 6-position of the pyridazine ring, although the nature of the side chain in the 3-position and of the substituent in the 4-position are also involved. Finally, the interpretation of the structure-activity relationships of the convulsant potency of the compounds in this series is complex, since altering either the side chain in the 3-position or the nature of the substituents in the 4- or in the 6-position modifies seizure threshold.

## Experimental Section

**Chemical Methods.** Melting points were obtained on a calibrated Kofler hot stage apparatus and are uncorrected. IR spectra were measured with a Beckman Acculab-4 spectrophotometer, and <sup>1</sup>H NMR spectra were recorded on a Bruker WP-60 spectrometer using the δ scale with reference to Me<sub>4</sub>Si for CDCl<sub>3</sub>

solutions. Chemical shifts were as expected and are only described for some selected compounds.

Some 3(2H)-pyridazinones are described in the literature. These are 4-methyl-6-phenyl-3(2H)-pyridazinone,<sup>1</sup> 6-phenyl-3(2H)-pyridazinone,<sup>37</sup> 4,6-diphenyl-3(2H)-pyridazinone,<sup>38,39</sup> 6-(p-hydroxyphenyl)-, 6-(m-chlorophenyl)-, 6-(o-chlorophenyl)-, 6-(p-methylphenyl)-, and 6-(p-methoxyphenyl)-4-methyl-3(2H)-pyridazinones,<sup>40</sup> 6-α-naphthyl-4-methyl-3(2H)-pyridazinone,<sup>41</sup> and 6-(p-nitrophenyl)-4-methyl-3(2H)-pyridazinone.<sup>42</sup> The corresponding 3-chloropyridazines have been prepared to synthesize GABA antagonists.<sup>42</sup>

Most of the new 3(2H)-pyridazinones were prepared by using methods A-C. A typical example for each method is given below.

**Method A (Scheme I).** 6-(3-Thienyl)-4-methyl-3(2H)-pyridazinone (92). A 2-L Erlenmeyer flask containing 70.4 g (0.8 mol) of pyruvic acid was cooled in an ice bath and the acid neutralized (phenolphthalein) with 20% KOH solution with stirring. 3-Acetylthiophene (0.8 mol) was added followed by a solution of 56 g of KOH pellets in 800 mL of methanol. The homogeneous mixture was kept at 4 °C for 96 h. The solution was then chilled in an ice bath and neutralized (phenolphthalein) with 10 N H<sub>2</sub>SO<sub>4</sub>, and the methanol was removed under reduced pressure. The residual mixture was acidified with 10 N H<sub>2</sub>SO<sub>4</sub>, diluted with water in order to dissolve the precipitated K<sub>2</sub>SO<sub>4</sub>, and extracted with three portions of diethyl ether. The combined ethereal layers were washed with brine and extracted with 400 mL of 10% KHCO<sub>3</sub>. The basic solution was washed with a small amount of ether and acidified with 10 N H<sub>2</sub>SO<sub>4</sub>. The crude keto acid precipitated and was recrystallized in water (or in benzene). Pure 3-(3-thienyl)-2-hydroxy-2-methylpropionic acid was obtained (25.5 g, 12%): <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.55 (s, 3 H, H<sub>3</sub>CCCH<sub>2</sub>), 3.46

(37) Lespagnol, A.; Deprey, J. *Bull. Soc. Chim. Fr.* 1962, II, 111.

(38) Steck, E. A.; Brundage, R. P. *J. Am. Chem. Soc.* 1953, 75, 1117.

(39) Jucker, E.; Suess, R. *Helv. Chim. Acta* 1959, 42, 2506.

(40) Laborit, H. *Belg. Pat.* 740582 (21 Oct. 1959) C.E.P.B.E.P.E.

(41) Steck, E.; Nachod, F. *J. Am. Chem. Soc.* 1957, 79, 4408.

(42) Wermuth, C. G.; Bourguignon, J. J.; Schlewer, G.; Gies, J. P.; Schoenfelder, A.; Melikian, A.; Bouchet, M. J.; Chantreux, D.; Molimard, J. C.; Heaulme, M.; Chambon, J. P.; Bizière, K. *J. Med. Chem.* 1987, 30, 239.

( $C_{AB}$ ,  $J_{AB} = 17.3$  Hz,  $\delta_A = 3.37$ ,  $\delta_B = 3.65$ , 2 H,  $CH_2CCH_3$ ), 7.34 (dd,  $J = 5.3$ ,  $J = 3.0$  Hz, 1 H,  $H_4$  thienyl), 7.54 (dd,  $J = 3.0$ ,  $J = 1.5$  Hz, 1 H,  $H_2$  thienyl).

The unreacted ketone can be recovered from the ethereal layer by evaporation and recrystallization (50 g).

To a solution of 25.3 g (0.12 mol) of 3-(3-thenoyl)-2-hydroxy-2-methylpropionic acid in 80 mL of 1-butanol contained in a Claisen flask was added 8.9 g (0.18 mol) of hydrazine hydrate. The water-butanol azeotrope was slowly distilled, followed by about 50 mL of pure butanol. After cooling, the expected 3-(2H)-pyridazinone crystallized. It was recrystallized in acetic acid, yielding 18 g (75%) of the title compound: mp 246 °C;  $^1H$  NMR (DMSO- $d_6$ )  $\delta$  1.98 (d,  $J = 0.7$  Hz, 3 H,  $H_3CC=CH$ ), 7.3–7.6 (m, 2 H,  $H_5$  thienyl), 7.76 (q,  $J = 0.7$  Hz, 1 H,  $HC=CH_3$ ), 7.8–8.0 (m, 1 H,  $H_2$  thienyl), 12.78 (s, 1 H,  $HNC=O$ ). Anal. C, H, N.

By the same procedure and starting from the appropriate methyl ketones, 3(2H)-pyridazinones 70, 73, 74, 76, 77, 79, 80, 86, 87, 88, 90, 91, and 92 were prepared (Table I).

**Method B (Scheme III).** 4-(2-Chlorobenzylidene)-6-phenyl-3(2H)-pyridazinone (68). (a)  $\alpha$ -(2-Chlorobenzylidene)- $\gamma$ -phenyl- $\beta$ , $\gamma$ -butenolide (120). A mixture of 53.5 g (0.3 mol) of  $\beta$ -benzoylpropionic acid, 33.6 mL (0.3 mol) of 2-chlorobenzaldehyde, 24.6 g (0.3 mol) of freshly fused sodium acetate, and 170 mL of acetic anhydride was maintained at 100 °C for 2 h. The hot solution was decanted from the sodium acetate, about 40 mL of 95% EtOH was added, and the mixture was kept at 4 °C for 3 h. The crystals were collected and washed first with a small amount of cold 95% ethanol followed by 200 mL of boiling water to remove any sodium acetate present. After drying, 59.6 g (71%) of the butenolide was obtained as a yellow solid which was pure enough for the following step. An analytical sample (mp 203.5 °C) could be obtained by recrystallization in AcOEt.

(b) 2-(2-Chlorobenzylidene)-3-benzoylpropionic Acid.<sup>33</sup> A mixture of 29.8 g (0.105 mol) of butenolide 120, 105 mL of 2 N NaOH, and 200 mL of 95% ethanol was refluxed for 1 h. After this time, the ethanol was removed, and the residue was diluted by means of 150 mL of water and acidified (pH = 1) with 10% HCl. The precipitated keto acid was collected, washed with water, dried, and recrystallized in 95% ethanol: yield 25 g (79%); mp 146 °C.

(c) 4-(2-Chlorobenzylidene)-6-phenyl-3(2H)-pyridazinone (68). 2-(2-Chlorobenzylidene)-3-benzoylpropionic acid (13) was cyclized with hydrazine hydrate as reported in method A (mp 150 °C).

Starting from the appropriate aldehydes, four new 3(2H)-pyridazinones (66–69) were prepared by using the same procedures (Table I).

**General Procedure for 3-Chloropyridazines.** A mixture containing the appropriate substituted 3(2H)-pyridazinone and phosphorus oxychloride (2 mL for 1 mmol) was heated at 80 °C for 2–6 h. After reduction of the excess volume of  $POCl_3$  by distillation under reduced pressure, the mixture was carefully poured on crushed ice. The water was rendered alkaline (20% NaOH). Crude 3-chloropyridazine was collected by filtration, washed with water, and dried under vacuum. The crude product was purified by chromatography on silica gel with a mixture of hexane-ethyl acetate as eluent or by recrystallization in 2-propanol or methanol.

Most of the new 3-chloropyridazines were prepared by using this procedure. Data are given in Table I.

**General Procedures for 3-[( $\beta$ -Morpholinoethyl)amino]-pyridazines.** Two methods (C, D) were used to prepare this compound.

**Method C.** A mixture of substituted 3-chloropyridazine (0.01 mol), an excess of the appropriate amine (0.05 mol), and 1 equiv of the corresponding amine hydrochloride (or ammonium chloride) was heated at 170 °C under argon with magnetic stirring for 1–1.5 h. The excess of amine was removed under reduced pressure. The residue was extracted with ethyl acetate, washed with water and brine, and dried over  $MgSO_4$ . After solvent evaporation, the product was crystallized and recrystallized with a mixture of ethyl ether-methanol.

**Method D.** A solution of substituted 3-chloropyridazine (0.01 mol) and 4–6 equiv of the appropriate amine in 1-butanol (25 mL) was refluxed for 48 h. The solvent was evaporated under reduced

pressure. The residue was then treated as described in method C.

Data are given in Table I.

The corresponding hydrochloride or hydrobromide were prepared by treating an ethereal solution of the base with gaseous hydrogen chloride or by adding 1 equiv of concentrated aqueous solution of hydrogen chloride or hydrogen bromide. Data are also given in Table I.

**Special Procedures (Scheme IV).** 4-(Ethoxycarbonyl)-6-phenyl-3(2H)-pyridazinone (15). (a) 4,5-Dihydro-4-(ethoxycarbonyl)-6-phenyl-3(2H)-pyridazinone. To a solution of 40.5 g (0.145 mol) of ethyl 2-carboxy-3-benzoylpropionate<sup>43,44</sup> in 70 mL of absolute ethanol cooled to 0 °C was added dropwise 7.3 g (0.145 mol) of hydrazine hydrate with stirring. The cooling bath was then removed and stirring was continued for 24 h. The expected dihydropyridazinone was then filtered off. An additional amount of 3.6 g (0.07 mol) of hydrazine hydrate was added to the filtrate, and after the mixture was allowed to stand for 24 h at room temperature, a second crop of the dihydropyridazinone was collected. The combined crops were purified either by recrystallization in ethanol or by column chromatography (silica gel, elution with 1:1 hexane-ethyl acetate). The yield was 21.5 g (60%) of a white powder: mp 158 °C; IR (KBr) 3310, 1740, 1675  $cm^{-1}$ ;  $^1H$  NMR ( $CDCl_3$ )  $\delta$  1.22 (t,  $J = 7.0$ , 3 H,  $OCH_2CH_3$ ), 3.1–3.7 (m, 3 H,  $CH_2CH(CO)_2$ ), 4.27 (q,  $J = 6.9$ , 2 H,  $OCH_2CH_3$ ), 7.4–8.0 (m, 5 H,  $C_6H_5$ ), 9.15 (br s, exchangeable with  $D_2O$ , 1 H, CONH).

(b) 4-(Ethoxycarbonyl)-6-phenyl-3(2H)-pyridazinone (15). To a solution of 9.0 g (0.036 mol) of dihydropyridazinone 121 in 200 mL of acetic acid was added dropwise a solution of 11.5 g (0.072 mol) of bromine in 50 mL of acetic acid. After complete reaction the solvent was evaporated under reduced pressure. To the residue was added 200 mL of water and the mixture was extracted with AcOEt. The collected organic layers were washed with brine and dried over  $MgSO_4$ , and the solvent was evaporated under reduced pressure. The residue was recrystallized in isopropyl alcohol or purified by chromatography (silica gel, elution with 1:1 cyclohexane-AcOEt): yield 5.8 g (60%) of pale yellow needles; mp 150 °C; IR (KBr) 3010, 1720, 1670  $cm^{-1}$ ;  $^1H$  NMR ( $CDCl_3$ )  $\delta$  1.43 (t,  $J = 7.2$  Hz, 3 H,  $OCH_2CH_3$ ), 4.47 (q,  $J = 7.2$  Hz, 2 H,  $OCH_2CH_3$ ), 7.5–7.8 (m, 5 H,  $C_6H_5$ ), 8.32 (s, 1 H). Anal. C, H, N.

4-(Aminocarbonyl)-6-phenyl-3(2H)-pyridazinone (20). A solution of 2 g (0.008 mol) of 4-(ethoxycarbonyl)-6-phenyl-3(2H)-pyridazinone (15) in 40 mL of concentrated ammonia (33%) was kept at 20 °C overnight. The aminocarbonyl derivative precipitated as a white powder: mp 300 °C; yield 86%; IR (KBr) 3330–3140, 1710, 1690  $cm^{-1}$ ;  $^1H$  NMR (DMSO- $d_6$ )  $\delta$  7.4–8.2 (m, 5 H,  $C_6H_5$ ), 8.50 (s, 1 H,  $HC=CC=O$ ), 8.90 (broad s, exchangeable with  $D_2O$ , 2 H, CONH $_2$ ). Anal. C, H, N.

3-Chloro-4-cyano-6-phenylpyridazine (21). A solution of 1.5 g (0.007 mol) of 4-(aminocarbonyl)-6-phenyl-3(2H)-pyridazinone (20) in 15 mL of phosphorus oxychloride was heated at 80–90 °C for 3 h. The excess of phosphorus oxychloride was removed in vacuo, and 50 mL of iced water was added. The expected pyridazine precipitated and was recrystallized in 2-propanol: yield 60%; mp 206 °C; IR ( $CHCl_3$ ) 2230  $cm^{-1}$ ;  $^1H$  NMR ( $CDCl_3$ )  $\delta$  7.5–8.2 (m, 5 H,  $C_6H_5$ ), 8.13 (s, 1 H,  $HCC=CCN$ ).

3-Chloro-4-(aminocarbonyl)-6-phenylpyridazine (18). A solution of 1.5 g (0.006 mol) of 3-chloro-4-(ethoxycarbonyl)-6-phenylpyridazine (16) in 60 mL of concentrated ammonia was stirred overnight at room temperature. The product was filtered off and dried in vacuo: mp 204 °C; yield 84%; IR (KBr) 3300–3150, 1670  $cm^{-1}$ ;  $^1H$  NMR (DMSO- $d_6$ )  $\delta$  6.15 (br s, 2 H, exchangeable with  $D_2O$ , CONH $_2$ ), 7.6–8.0 (m, 5 H,  $C_6H_5$ ), 8.41 (s, 1 H,  $HCC=CCONH_2$ ).

3-[( $\beta$ -Morpholinoethyl)amino]-4-methyl-6-(4-amino-

(43) Bisagni, E.; Marquet, J. P.; Andre-Lousert, J. *Bull. Soc. Chim. Fr.* 1969, II, 4338.

(44) Ray, R. M.; Ray, J. N. *J. Chem. Soc.* 1925, 127, 2721.

(45) Worms, P.; Kan, J. P.; Wermuth, C. G.; Roncucci, R.; Bizière, K. *J. Pharmacol. Exp. Ther.* 1987, 240, 241.

(46) Kan, J. P.; Steinberg, R.; Mouget-Goniot, C.; Worms, P.; Bizière, K. *J. Pharmacol. Exp. Ther.* 1987, 240, 251.

(47) Worms, P.; Kan, J. P.; Wermuth, C. G.; Bizière, K. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 1986, 334, 246.



**phenylpyridazine (54).** A solution of 0.3 g (0.0009 mol) of 3-[(morpholinoethyl)amino]-4-methyl-6-(4-nitrophenyl)pyridazine (55) in 70 mL of ethyl ether was saturated with gaseous hydrogen chloride. The mixture was hydrogenated at 2–4 atm over 10% Pd/C for 1 h. Filtration and evaporation to dryness gave 0.25 g (60%) of reduced product 54:  $^1\text{H NMR}$  ( $\text{D}_2\text{O}$ )  $\delta$  2.05 (br s, 3 H,  $\text{H}_3\text{CC}=\text{CH}$ ), 3.2–3.6 (m, 6 H,  $(\text{CH}_2)_3\text{N}$ ), 3.6–4.1 (m, 6 H,  $\text{O}(\text{CH}_2)_2 + \text{NHCH}_2$ ), 6.8–8.4 (m, 6 H,  $\text{C}_6\text{H}_5 + \text{HC}=\text{CCH}_3$ ). Anal. (hydrochloride, 1.5 $\text{H}_2\text{O}$ ) C, H, N.

**3-[( $\beta$ -Morpholinoethyl)amino]-4-methyl-6-(2-hydroxyphenyl)pyridazine (58), 3-[( $\beta$ -Morpholinoethyl)amino]-4-methyl-6-(3-hydroxyphenyl)pyridazine (57), and 3-[( $\beta$ -Morpholinoethyl)amino]-4-methyl-6-(4-hydroxyphenyl)pyridazine (56).** These compounds were prepared by hydrolysis of the corresponding methoxyphenyl derivatives. The procedure is illustrated for compound 56.

**3-[( $\beta$ -Morpholinoethyl)amino]-4-methyl-6-(4-methoxyphenyl)pyridazine (51)** (19 g, 0.06 mol) was refluxed in 150 mL of a mixture of acetic acid (100 mL) and concentrated aqueous hydrogen bromide (50 mL) (or hydrogen chloride) for 6 h. The solvents were removed. The oil crystallized upon dissolution in ethyl alcohol and ether addition. It was recrystallized in ethyl alcohol: mp 162 °C; yield 78% (21.5 g);  $^1\text{H NMR}$  ( $\text{D}_2\text{O}$ )  $\delta$  2.36 (br s, 3 H,  $\text{H}_3\text{C}=\text{CH}$ ), 3.3–3.7 (m, 6 H,  $(\text{CH}_2)_3\text{N}$ ), 3.8–4.2 (m, 6 H,  $\text{O}(\text{CH}_2)_2$ ), 7.35 ( $\text{C}_{\text{AB}}\text{H}_2$ ,  $J_{\text{AB}} = 8.0$ ,  $\sigma = 0.67$ , 4 H,  $\text{C}_6\text{H}_4$ ), 7.87 (br s, 1 H,  $\text{HC}=\text{CCH}_3$ ). Anal. C, H, N.

**3-[(Aminopropyl)amino]-4-methyl-6-phenylpyridazine (26).** 3-Chloro-4-methyl-6-phenylpyridazine (7) (12.0 g, 0.058 mol) and a large excess of ethylenediamine (35 g, 0.58 mol) were heated at 100 °C under nitrogen for 3 h. The excess diamine was then eliminated under reduced pressure. The oily residue was dissolved in water. The pH was adjusted to pH 9 by means of 2 N sodium hydroxide solution. The aqueous solution was saturated with sodium chloride and extracted with methylene chloride. The organic phase was washed with brine and dried over magnesium sulfate. The solvent was removed, affording a yellow oil (11.5 g). The free base was crystallized by trituration with a mixture of 2-propanol and 2-propanol oxide. Mother liquors contain the symmetrically disubstituted amine and small amounts of free diamine. The product could also be purified by chromatography on silica gel. The symmetrically disubstituted compound was eluted with a mixture of ethyl acetate–methanol (75:25) and the expected product with pure methanol: mp 219–221 °C; yield 10.5 g (80%); IR (KBr) 3270, 2900, 2740, 2650, 1600, 1560  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  ( $\text{DMSO}-d_6$ )  $\delta$  2.25 (d,  $J = 1.0$  Hz, 3 H,  $\text{HC}=\text{CH}_3$ ), 3.15 (t,  $J = 6.0$  Hz, 2 H,  $\text{H}_2\text{NCH}_2$ ), 3.75 (t,  $J = 6.0$  Hz, 2 H,  $\text{HNCH}_2$ ), 4.70 (br s, 2 H, exchangeable with  $\text{D}_2\text{O}$ ,  $\text{CH}_2\text{NH}_2$ ), 6.80 (br s, 1 H, exchangeable with  $\text{D}_2\text{O}$ ,  $\text{NHCH}_2$ ), 7.3–8.1 (m, 5 H,  $\text{C}_6\text{H}_5$ ), 7.75 (q,  $J = 1.0$ , 1 H,  $\text{HC}=\text{CH}_3$ ).

**3-[( $\beta$ -Aminopropyl)amino]-4-methyl-6-phenylpyridazine (27) and 3-[(4-aminobutyl)amino]-4-methyl-6-phenylpyridazine (29)** were prepared in the same way, replacing ethylenediamine with propylenediamine and butylenediamine, respectively.

**3-[(2-Aminopropyl)amino]-4-methyl-6-phenylpyridazine and 3-[[1-(Methyleneamino)ethyl]amino]-4-methyl-6-phenylpyridazine.** The 75:25 mixture of these two isomers was obtained by heating 11 g (0.054 mol) of 3-chloro-4-methyl-6-phenylpyridazine and an excess of 40 g (0.54 mol) of 1,2-diaminopropane under argon at 100 °C for 3.5 h (it is also possible to add 1 equiv of ammonium chloride to shorten the reaction time to 2 h). The excess of diamine was then removed, affording a yellow oil. The mixture of isomers was isolated by chromatography on silica gel (eluent methanol–triethylamine, 95:5). Anal. C, H, N.  $^1\text{H NMR}$  ( $\text{DMSO}-d_6$ ): the 75:25 ratio between the two isomers was established by NMR. Main isomer: 1.08 (d,  $J = 6.0$  Hz, 3 H,  $\text{CH}(\text{CH}_3)\text{N}$ ), 2.22 (d,  $J = 1.0$  Hz, 3 H,  $\text{HC}=\text{CH}_3$ ), 2.45–2.85 (m, 4 H,  $\text{HNCH}_2$  and protons exchangeable by  $\text{D}_2\text{O}$ ,  $\text{NH}_2$ ), 3.1–3.55 (m, 1 H,  $\text{HCNH}_2$ ), 6.4 (t,  $J = 5.5$  Hz, 1 H,  $\text{NHCH}_2$ ), 7.3–8.2 (m, 6 H,  $\text{HC}=\text{CH}_3$  and 6-phenyl). Minor isomer (25%): 1.26 (d,  $J = 6.0$  Hz, 3 H,  $\text{HNCH}(\text{CH}_3)\text{CH}_2$ ), 4.4–4.6 (m, 1 H,  $\text{HNCH}(\text{CH}_3)\text{CH}_2$ ), 5.9 (d,  $J = 5.5$  Hz, 1 H,  $\text{NHCH}(\text{CH}_3)$ ).

**Pharmacological Methods.** Female albino mice (CD1 strain, Charles River France) weighing 18–22 g (reserpine and 5-HTP tests) or 25–30 g (turning) were used. The test compounds were dissolved or suspended in distilled water with gum tragacanth

and administered intraperitoneally (ip) to groups of 7–20 mice per dose at multiple dose levels. The following tests were performed: evaluation of acute toxicity with graphic calculation of a 50% lethal dose ( $\text{LD}_{50}$ ). Drugs or vehicle were injected to groups of 5–10 mice, which were then observed for 6–8 h. Lethality was recorded up to 72 h after drug administration.

Antagonism of reserpine-induced ptosis in mice was performed according to the method described by Gouret et al.<sup>34</sup> modified by Worms et al.<sup>13</sup> Drugs or vehicle were administered simultaneously with reserpine (2 mg/kg iv). One hour later, mice were observed individually for the occurrence or absence of palpebral ptosis, on an all-or-none basis (ptosis defined as closing of half, or more, of the palpebra). All control animals exhibited ptosis.

Potential of L-5-HTP-induced tremor in mice was performed according to the method described by Lessin.<sup>35</sup> Drugs or vehicle were injected 30 min before a threshold dose of L-5-HTP (200 mg/kg ip). Mice were isolated in small plexiglass cages (10  $\times$  10  $\times$  10 cm). Tremor was assessed on an all-or-none basis during the 20 min following L-5-HTP. Tremor occurred in 0–20% of the control animals.

Decrease of the spontaneous turning in mice bearing a unilateral 6-OHDA lesion of the striatum. For this latter test, the procedure described by Von Voigtlander and Moore<sup>36</sup> was slightly modified. The right nigrostriatal dopaminergic pathway was lesioned by stereotaxic injection of 10  $\mu\text{g}$  (in 1  $\mu\text{L}$  of saline containing 1 mg/mL of ascorbic acid) of 6-hydroxydopamine (6-OHDA) into the right striatum of anesthetized mice (pentobarbitone, 60 mg/kg ip). Seven days later, animals exhibited a spontaneous turning behavior, to the right (ipsilateral). At this time, the drugs or vehicle was injected ip, and the number of turns was counted 30 min later, during a period of 2 min. Control animals exhibited a rate of about 10 ipsilateral turns in 2 min. Percent antagonism of control values were calculated and data were expressed as minimal effective dose (MED) or the first dose that significantly decreased the spontaneous turning measured in controls ( $p < 0.05$ ).

For the reserpine and 5-HTP models, effective 50% doses (ED 50) were calculated, with their 95% confidence limits, by log-probit analysis. The paired Student's  $t$  test was used to assess significance in the turning experiments.

**Acknowledgment.** The technical assistance of V. Zerr and A. Schoenfelder is gratefully acknowledged. Special thanks are also due to M. Wernert for typing the manuscript.

**Registry No.** 1, 118269-66-2; 2, 98-86-2; 4, 13299-97-3; 4 (3-thienyl analogue), 118270-23-8; 5, 28657-45-6; 6, 13300-09-9; 7, 28657-39-8; 12 ( $\text{R}_1 = \text{Cl}-o\text{-Ph}$ ,  $\text{R}_2 = \text{Ph}$ ), 118269-67-3; 14, 94011-49-1; 15, 34753-27-0; 16, 34750-70-4; 17, 118269-68-4; 17 (free base), 118270-50-1; 18, 118269-69-5; 19, 118269-70-8; 19 (free base), 118275-18-6; 20, 87769-56-0; 21, 94011-64-0; 22, 94011-81-1; 22 (free base), 94011-82-2; 23, 25905-57-1; 23 (free base), 25905-78-6; 24, 118269-71-9; 24 (free base), 118270-24-9; 25, 118269-72-0; 25 (free base), 118270-25-0; 26, 118269-73-1; 26 (free base), 85714-56-3; 27, 86662-99-9; 27 (free base), 86662-98-8; 28 (isomer 1), 86663-04-9; 28 (isomer 1, free base), 118270-26-1; 28 (isomer 2), 86663-03-8; 28 (isomer 2, free base), 118270-51-2; 29, 86663-01-6; 29 (free base), 86663-00-5; 30, 86672-44-8; 30 (free base), 118270-27-2; 31, 118269-74-2; 31 (free base), 40064-50-4; 32, 118269-75-3; 32 (free base), 40064-48-0; 33, 118269-77-5; 33 (free base), 118269-76-4; 34, 118269-78-6; 34 (free base), 118270-28-3; 35, 118269-79-7; 35 (free base), 118270-29-4; 36, 40064-51-5; 36 (free base), 40064-52-6; 37, 40064-54-8; 37 (free base), 40064-55-9; 38, 118269-80-0; 38 (free base), 118270-30-7; 39, 118269-81-1; 39 (free base), 118270-31-8; 40, 118269-82-2; 40 (free base), 118270-32-9; 41, 118269-83-3; 41 (free base), 118270-33-0; 42, 118269-84-4; 42 (free base), 118270-34-1; 43, 118269-85-5; 43 (free base), 118270-35-2; 44, 118269-86-6; 44 (free base), 118270-36-3; 45, 118269-87-7; 45 (free base), 118270-37-4; 46, 118269-88-8; 46 (free base), 118270-38-5; 47, 118269-89-9; 47 (free base), 118270-39-6; 48, 118269-90-2; 48 (free base), 118270-40-9; 49, 118269-91-3; 49 (free base), 118270-41-0; 50, 118269-92-4; 50 (free base), 118270-42-1; 51, 118269-93-5; 51 (free base), 40064-53-7; 52, 118269-94-6; 52 (free base), 118270-43-2; 53, 118269-95-7; 53 (free base), 118270-44-3; 54, 118269-96-8; 54 (free base), 118270-45-4; 55, 118269-97-9; 55 (free base), 118270-46-5; 56, 86663-17-4; 56 (free base), 82239-52-9; 57, 86663-19-6; 57 (free base), 101969-83-9; 58, 118269-98-0; 58

(free base), 86663-23-2; 59, 118269-99-1; 59 (free base), 118270-47-6; 60, 94221-58-6; 60 (free base), 94221-57-5; 61, 118270-00-1; 61 (free base), 118270-48-7; 62, 118270-01-2; 62 (free base), 118270-49-8; 63, 40064-41-3; 63 (free base), 40064-46-8; 64, 94221-54-2; 64 (free base), 94221-53-1; 65, 94275-65-7; 65 (free base), 94275-66-8; 66, 20153-14-4; 67, 58050-61-6; 68, 66122-39-2; 69, 118270-02-3; 70, 32193-12-7; 71, 28657-56-9; 72, 28657-55-8; 73, 68612-32-8; 74, 118270-03-4; 75, 21004-61-5; 76, 118270-04-5; 77, 118270-05-6; 78, 28657-53-6; 79, 118270-06-7; 80, 118270-07-8; 81, 118270-08-9; 82, 118270-09-0; 83, 118270-10-3; 84, 118270-11-4; 85, 118270-12-5; 86, 7007-92-3; 87, 94221-59-7; 88, 118270-13-6; 89, 28657-58-1; 90, 28734-27-2; 91, 28657-57-0; 92, 94221-55-3; 93, 64657-83-6; 94, 118270-14-7; 95, 118270-15-8; 96, 118270-16-9; 97, 28657-38-7; 98, 28657-40-1; 99, 32176-53-7; 100, 68415-29-2; 101, 118270-17-0; 102, 60855-47-2; 103, 60855-49-4; 104, 60855-51-8; 105, 28734-31-8; 106, 60855-46-1; 107, 106982-18-7; 108, 118270-18-1; 109, 118270-19-2;

110, 60855-53-0; 111, 118270-20-5; 112, 118270-21-6; 113, 17258-26-3; 114, 94221-60-0; 115, 118270-22-7; 116, 28657-42-3; 117, 28734-28-3; 118, 32176-55-9; 119, 94221-56-4; 120, 13294-93-4; 121, 94011-50-4; pyruvic acid, 127-17-3; 4'-chloroacetophenone, 99-91-2; 4'-fluoroacetophenone, 403-42-9; 2'-fluoroacetophenone, 445-27-2; 3'-methylacetophenone, 585-74-0; 2'-methylacetophenone, 577-16-2; 3'-methoxyacetophenone, 586-37-8; 2'-methoxyacetophenone, 579-74-8; acetone, 67-64-1; 1-phenyl-2-propanone, 103-79-7; cyclohexyl methyl ketone, 823-76-7; 2-acetylnaphthalene, 93-08-3; 2-acetylthiophene, 88-15-3; 3-acetylthiophene, 1468-83-3; benzaldehyde, 100-52-7; 4-chlorobenzoic acid, 74-11-3; 2-chlorobenzoic acid, 118-91-2; 2-naphthalenecarboxaldehyde, 66-99-9;  $\beta$ -benzoylpropionic acid, 2051-95-8;  $\beta$ -morpholinoethylamine hydrochloride, 90746-30-8;  $\beta$ -morpholinoethylamine, 2038-03-1; ethylenediamine, 107-15-3; propylenediamine, 78-90-0; 1,4-butanediamine, 110-60-1.

## Fluoronaphthyridines and Quinolones as Antibacterial Agents. 1. Synthesis and Structure-Activity Relationships of New 1-Substituted Derivatives

D. Bouzard,\*† P. Di Cesare,† M. Essiz,† J. P. Jacquet,† P. Remuzon,† A. Weber,† T. Oki,† and M. Masuyoshi†

Centre de Recherche Bristol-Myers, BP 62, Marne La Vallee, 77422 Torcy, France, and Bristol-Myers Research Institute, Ltd., 2-9-3 Shimo-Meguro, Meguro-Ku, Tokyo 153, Japan. Received April 6, 1988

A series of novel 7-piperazinyl-1-substituted-6-fluoroquinolones and naphthyridines have been prepared and their antibacterial activities evaluated. These derivatives are characterized by having alkyl, alkenyl, arylalkyl, cycloalkyl, and cycloalkenyl groups at the 1-position. As a result of this study, derivatives 7 and 26, which are substituted with *tert*-butyl groups at N-1, were found to possess excellent in vitro and in vivo potency, particularly against *Staphylococcus aureus*, comparable to that of norfloxacin (1) or ciprofloxacin (10). Structure-activity relationships of N-1 substituted alkyls and cycloalkyls are also discussed.

In the intense work on the class of quinolone antibacterials, basically two types of compounds can clearly be distinguished: the first group, typified by oxolinic acid and nalidixic acid, lack Gram-positive activity, while the second type, including norfloxacin<sup>2</sup> and enoxacin,<sup>3</sup> are compounds with relatively broad spectra. A number of new compounds, such as ciprofloxacin,<sup>4</sup> ofloxacin,<sup>5</sup> CI 934,<sup>6</sup> and difloxacin,<sup>7</sup> were prepared and tested, and many of them were found to be useful antibacterial agents and are in advanced development or already marketed.

These compounds share common structural features. Earlier<sup>1</sup> and more recent structure-activity relationship (SAR) studies<sup>8,9</sup> concluded that the optimal aliphatic group to attach to N-1 should be ethyl, vinyl, or a bioisostere of ethyl. Recently, several highly potent analogues have been developed that bring doubts and induce questions on the universality of this concept. Ciprofloxacin (*N*-cyclopropyl), ofloxacin (tricycle), and difloxacin (*N*-aryl) are examples of such compounds.

On the basis of former conclusions, systematic modification of the alkyl N-1 substituent received little attention. This laboratory explored and complemented data on the effect of the N-1 substituent on the antibacterial activity to update the SAR on quinolone antibacterials (see Figure 1a,b). In this paper, we report the synthesis and antibacterial activity of 7-(1-piperazinyl)-6-fluoro- and -6,8-difluoro-1-substituted-1,4-dihydro-4-oxoquinoline-3-carboxylic acids and 7-(1-piperazinyl)-6-fluoro-1-substituted-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids (Tables I and II).

### Chemistry

The general method used for the preparation of 4-oxoquinolones and naphthyridines is illustrated in Scheme I and was adapted from synthetic routes reported for analogues.<sup>7,10,14-16</sup> Reaction of ethyl 2-(2,4-dichloro-5-

- (1) Albrecht, R. *Prog. Drug. Res.* 1977, 21, 9.
- (2) Koga, H.; Itoh, A.; Murayama, S.; Suzue, S.; Irikura, T. *J. Med. Chem.* 1980, 23, 1358.
- (3) Matsumoto, J.; Miyamoto, T.; Minamida, A.; Nishimura, Y.; Egawa, H.; Nishimura, H. *J. Med. Chem.* 1984, 27, 292.
- (4) Wise, R.; Andrews, J. M.; Edwards, L. J. *Antimicrob. Agents Chemother.* 1983, 23, 559.
- (5) Hayakawa, I.; Tanaka, Y.; Hirimatsu, T. *Eur. Pat. Appl.* 47005; *Chem. Abstr.* 1982, 97, 55821.
- (6) Culbertson, T. P.; Mich, T. F.; Domagala, J. M.; Nichols, J. B. *Eur. Pat. Appl.* 106489; *Chem. Abstr.* 1984, 101, 72740.
- (7) Chu, D. T. W.; Fernandes, P. B.; Claiborne, A. K.; Pihuleac, E.; Nordeen, C. W.; Maleczka, R. E.; Pernet, A. G. *J. Med. Chem.* 1985, 28, 1558.
- (8) Fujita, T. *The role of QSAR in drug design.* In *Drug Design: Fact or fantasy?* Jolles, G., Wooldridge, K. R. H., Eds.; Academic Press: New York, 1984.
- (9) Matsumoto, J. I.; Nishimura, Y.; Minamida, A. *Chem. Pharm. Bull.* 1988, 36, 1223.
- (10) During the course of this work a related patent appeared: Hokuriku Pharm. Co. Ltd., Jpn. Kohai Tokkyo Koho 60 28,964; *Chem. Abstr.* 1985, 103, 71202.
- (11) Kyorin Pharm. Co. Ltd., Belg. Patent 899,399; *Chem. Abstr.* 1985, 102, 45791.
- (12) Following completion of this work another patent appeared: Schriewer, M.; Grohe, K.; Zeiler, H. J.; Metzger, K. G. German Patent 3,509,546; *Chem. Abstr.* 1986, 106, 4900.
- (13) Petersen, U.; Grohe, K.; Zeiler, H. J.; Metzger, K. G. German Patent 3,508,816; *Chem. Abstr.* 1986, 105, 191059.
- (14) Chu, D. T. W.; Fernandes, P. B.; Claiborne, A. K.; Gracey, E. H.; Pernet, A. G. *J. Med. Chem.* 1986, 29, 2363.

\* Centre de Recherche Bristol-Myers.

† Bristol-Myers Research Institute Ltd.